Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Though it is still very early on, BTK degrader BGB-16673 appears tolerable. Clinical trials of BTK degraders may be especially of interest to CLL patients
A new clinical trial is recruiting patients with relapsed / refractory B-cell cancers to test the safety of a new experimental MALT1 inhibitor.
Clinician Resource Library: Partnered CME Offerings From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care (PeerView: Activity expires 2/16/25) Toward a Brighter Future for Preventing COVID-19
The majority of CLL patients who had previously relapsed on covalent BTK inhibitors responded well to pirtobrutinib therapy.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
March 2024 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
NX-2127 is a new type of drug that degrades BTK. Phase 1 clinical trial data shows that it has a manageable safety profile in patients with CLL / SLL.
On Dec. 1, 2023, pirtobrutinib received accelerated approval from the FDA for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients who had failed two prior lines of therapy, including a BTK inhibitor (BTKi) and a BCL-2 inhibitor.
For most CLL (chronic lymphocytic leukemia) patients who have received six years of continuous ibrutinib treatment, the levels of residual disease decrease or remain stable for the subsequent 6-12 months after stopping ibrutinib.
One click to our most popular content.
